在天体细胞质瘤中多囊素表达.
Martha Assimakopoulou1, Konstantina Soufli1, Maria Melachrinou2
1Department of Anatomy, Histology and Embryology, School of Medicine, University of Patras, 26504 Patras, Greece.
Biomedicines
|April 29, 2025
概括
多囊素1 (PC1) 和多囊素2 (PC2) 基因在星系细胞瘤,特别是质母细胞瘤中被上调. 它们的增加表达与质瘤患者的预后较差相关,这表明它们在瘤发育中的作用.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 遗传学 遗传学是一种遗传学.
背景情况:
- 多素1 (PC1) 和多素2 (PC2) 是由PKD1和PKD2基因编码的TRP通道蛋白.
- 虽然已知自体主导性多囊性病,但多囊素与固体瘤的发病有关.
- 人类星系细胞瘤中PKD1和PKD2的表达在很大程度上仍然没有表征.
研究的目的:
- 为了研究PKD1和PKD2基因表达在天体细胞瘤中.
- 为了将PC1和PC2蛋白表达与天体细胞瘤的临床病理特征相关联.
- 评估多囊素表达与瘤等级,患者年龄和性别之间的关系.
主要方法:
- 检查了70个星细胞瘤病例 (8级二,12级三,50级四).
- 使用qRT-PCR (ΔΔCt方法) 量化PKD1和PKD2的mRNA水平.
- 通过免疫组织化学检测PC1和PC2蛋白表达 (H分数系统).
主要成果:
- 与正常大脑组织相比,PKD1和PKD2的mRNA水平以及PC1和PC2蛋白在星细胞瘤中显著升高.
- 质母细胞瘤 (IV级) 显示PKD1,PKD2,PC1和PC2表达的最大增加.
- PC1的表达与患者年龄相关,PC1和PC2都与p53免疫表达在特定程度上存在相关性. PKD1和PKD2表达与质瘤预后负相关.
结论:
- 多囊素 (PC1和PC2) 可能参与星细胞瘤的发病.
- 在星细胞瘤,特别是质母细胞瘤中,多囊素的高表达表明在瘤进展中发挥了作用.
- 需要进一步的研究,以阐明多囊素参与天体细胞瘤发展的确切机制.
相关概念视频
Cancers Originate from Somatic Mutations in a Single Cell
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
The Tumor Microenvironment
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Cancer Stem Cells and Tumor Maintenance
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer-Critical Genes II: Tumor Suppressor Genes
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
The Tumor Microenvironment
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.


